August 13, 2013

MRA, Leading Melanoma Research Funder, Announces Annual Request for Proposals

The Melanoma Research Alliance (MRA) today announced its seventh annual Request for Proposals (RFP), soliciting translational research grant applications from scientists and clinicians around the world. The RFP calls for ideas that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment. MRA will accept proposals for Young Investigator Awards, Academic-Industrial Partnership Awards, and Team Science Awards. This year, the RFP includes MRA’s first Regional Special Opportunity, soliciting Team Science Award proposals from Israel-based investigators. During this 2014 grant cycle, the organization plans to award at least $8 million to new projects. More details on award types, deadlines, and eligibility criteria can be found at: http://www.curemelanoma.org/research/request-for-proposals/.

MRA is the largest non-profit foundation focused on funding high-impact melanoma research and has awarded more than $48 million over its seven-year history. Since its founding, MRA has worked to engage preeminent melanoma researchers, world-class academic institutions, and the world’s leading biopharmaceutical, biotech, and device companies in a common mission to end suffering and death due to melanoma.

Melanoma is a leading cause of new cancers, and more effective options for early detection, prevention, diagnosis, and treatment are urgently needed. Recent scientific and clinical advances have provided new hope for patients, but much work remains to be done as MRA continues to work toward the day when no one will suffer or die from melanoma.

About The Melanoma Research Alliance
MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma. MRA’s ability to fund wide-ranging research in melanoma is amplified by unique multi-faceted collaborations and partnerships with individuals, private foundations and corporations. For more information, please visit www.curemelanoma.org.